Legend Biotech Corp (NASDAQ: LEGN)

Legend Biotech Corp, a global, clinical-stage biopharmaceutical company, is at the forefront of discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. The company's lead product candidate, cilta-cel, is an autologous CAR-T cell therapy that targets the BCMA protein in multiple myeloma (MM). Cilta-cel has demonstrated promising results in clinical trials, with a 97.9% overall response rate (ORR) and a median duration of response (DOR) of 33.9 months in a Phase 1b/2 trial.

Legend Biotech operates through its subsidiaries, primarily located in the United States, China, and Europe. The company has a strong team with broad experience in biopharmaceutical drug discovery, development, and commercialization. Its strategy is focused on advancing cilta-cel through registrational trials and obtaining approval for the treatment of MM globally.

The company generates revenue through the development and commercialization of cell therapies, including cilta-cel, and through collaborations with partners such as Janssen. Legend Biotech's competitive advantages include its proprietary CAR-T technology platform, its experienced team with broad experience in biopharmaceutical drug discovery, development, and commercialization, its global clinical development strategy, and its manufacturing capabilities.

Legend Biotech's primary business activities include discovery and development of novel cell therapies for oncology and other indications, manufacturing and commercialization of cell therapies, clinical trials and regulatory submissions, research and development of new product candidates, and collaboration with partners to develop and commercialize cell therapies.

The company's key customers include patients with relapsed and refractory multiple myeloma, healthcare providers, including hospitals and clinics, and pharmaceutical companies, such as Janssen.

The company's pipeline includes several product candidates, including cilta-cel, an autologous CAR-T cell therapy targeting BCMA in MM, and LB2102, an investigational, autologous CAR-T therapy targeting DLL-3 in extensive stage small cell lung cancer.

In terms of intellectual property, Legend Biotech owns 87 issued patents and 546 pending patent applications around the world covering its development platforms, commercial product, clinical products, and preclinical products. The company also relies on trade secrets and know-how to protect its proprietary information.

The company has entered into several collaborations and license agreements, including a collaboration and license agreement with Janssen to develop and commercialize cilta-cel, and a license agreement with Novartis to develop and commercialize LB2102. Under these agreements, Legend Biotech grants Janssen and Novartis exclusive worldwide licenses to develop and commercialize cilta-cel and LB2102, respectively, and receives milestone payments and royalties on net sales.

In terms of commercialization, Legend Biotech has established a sales, marketing, and operational infrastructure to support the commercialization of cilta-cel in the United States. The company also has a global commercialization plan in place for cilta-cel, which includes partnering with Janssen to commercialize the product in all countries excluding the United States and Greater China.